Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 637 participants.

Also called NCT03299244

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 637 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03299244
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China, India, Malaysia, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03299244. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-15 (actual); primary completion 2020-04-08 (actual). Results posted on 2021-04-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
Condition
Secondary Hyperparathyroidism
Intervention (Drug)
Etelcalcetide
Intervention (Drug)
Cinacalcet
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct03299244
Content hash
9c7c3993d35d2fdf8dca5e82cc2142f740ee5b0aca9da7612197124da860b0fd